Abbott Laboratories Profit Jumps As All Business Units Shine

NEW YORK (Reuters) - Abbott Laboratories said on Wednesday fourth-quarter earnings jumped 28 percent on demand for its prescription drugs, nutritional products and medical devices, including its new Xience stent used to prop open coronary arteries.

MORE ON THIS TOPIC